Your browser doesn't support javascript.
loading
A new avenue for treating neuronal diseases: Ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects.
Tai, Chun-Hwei; Bellesi, Michele; Chen, An-Chih; Lin, Chih-Li; Li, Hsin-Hua; Lin, Pin-Jiun; Liao, Wen-Chieh; Hung, Ching-Sui; Schwarting, Rainer K; Ho, Ying-Jui.
Afiliación
  • Tai CH; Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 10002, Taiwan, ROC.
  • Bellesi M; Department of Experimental and Clinical Medicine, Section of Neuroscience and Cell Biology, Universita Politecnica delle Marche, Ancona, Italy.
  • Chen AC; Department of Neurology, Chung Shan Medical University Hospital, Taichung, 402, Taiwan, ROC.
  • Lin CL; Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan, ROC.
  • Li HH; Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan, ROC.
  • Lin PJ; Department of Psychology, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, 402, Taiwan, ROC.
  • Liao WC; Department of Anatomy, Faculty of Medicine, Chung Shan Medical University, Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, 402, Taiwan, ROC.
  • Hung CS; Occupational Safety and Health Office, Taipei City Hospital, Taipei, 10581, Taiwan, ROC. Electronic address: bessyhung@gmail.com.
  • Schwarting RK; Behavioral Neuroscience, Experimental and Biological Psychology, Philipps-Universität Marburg, 35032, Marburg, Germany. Electronic address: schwarti@staff.uni-marburg.de.
  • Ho YJ; Department of Psychology, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, 402, Taiwan, ROC. Electronic address: yjho@csmu.edu.tw.
Behav Brain Res ; 364: 149-156, 2019 05 17.
Article en En | MEDLINE | ID: mdl-30768995
ABSTRACT
Several neurodegenerative disorders, namely Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease, share common pathophysiological features, such as (1) cognitive deficits, (2) glutamatergic hyperactivity-related excitotoxicity, and (3) deposition of α-synuclein (α-syn) and ß-amyloid (Aß). Ceftriaxone (CEF) is a well-tested and safe drug that has been used as an antibiotic for several decades. Recent studies have demonstrated the following effects of CEF (1) increasing glutamate transporter-1 expression and glutamate reuptake and suppressing excitotoxicity, (2) binding well with α-syn and inhibition of α-syn polymerization, (3) modulating expression of genes related to Aß metabolism, and (4) enhancing neurogenesis and recovery of neuronal density. In addition, our data revealed that CEF ameliorates seizure and abnormal neuronal firing in the brain. These results suggest the potential of CEF in treating neuronal disorders. This paper addresses the effects and pharmacology of CEF.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ceftriaxona / Enfermedades Neurodegenerativas Límite: Humans Idioma: En Revista: Behav Brain Res Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ceftriaxona / Enfermedades Neurodegenerativas Límite: Humans Idioma: En Revista: Behav Brain Res Año: 2019 Tipo del documento: Article